Mary Falzon

University College London Hospitals NHS Foundation Trust — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

48h-index16.3kcitations197works9.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(53), Lung Cancer Treatments and Mutations(33), Breast Cancer Treatment Studies(23), Lung Cancer Diagnosis and Treatment(21), Cancer Immunotherapy and Biomarkers(20)

Publications182 total

Supplementary Tables S1-S8 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
2025Open Access
Supplementary Figures S1-S25 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
2025Open Access
Somatic evolution following cancer treatment in normal tissue
Nature·2025Open Access
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma
Genome biology·2025Open Access
DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution
Nature Genetics·2025· 4 citedOpen Access
Aberrant basal cell clonal dynamics shape early lung carcinogenesis
Science·2025· 7 citedOpen Access
ImmuneLENS characterizes systemic immune dysregulation in aging and cancer
Nature Genetics·2025· 6 citedOpen Access
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Nature Cancer·2025· 7 citedOpen Access
Data from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
2024Open Access
Supplementary Tables S1-S8 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
2024Open Access
Supplementary Figures S1-S25 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
2024Open Access
Supplementary Figures S1-S25 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
2024Open Access
Supplementary Tables S1-S8 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
2024Open Access
Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx
Nature·2024· 3 citedOpen Access
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones
Nature Communications·2023· 10 citedOpen Access
Supplementary Tables S1-S8 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
2023Open Access
Figure 6 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
2023Open Access
Figure 6 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
2023Open Access
Supplementary Figures S1-S25 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
2023Open Access
Figure 3 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Sam M. Janes(20), Sophia Ward(17), Nicholas McGranahan(15), Charles Swanton(15), Selvaraju Veeriah(14), Sergio A. Quezada(14), Mariam Jamal‐Hanjani(13), Nicolai J. Birkbak(13), David A. Moore(13), Siow Ming Lee(13), Martin Förster(13), Andrew Rowan(12), Tanya Ahmad(12), Crispin T. Hiley(12), Peter Van Loo(12), Gareth A. Wilson(11), Rachel Rosenthal(11), Samra Turajlic(11), Teresa Marafioti(11), Jenny Donovan(11)